NASDAQ:EYES - Second Sight Medical Products Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.09
▼ -0.03 (-1.42%)

This chart shows the closing price for EYES by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Second Sight Medical Products Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EYES and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EYES

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Second Sight Medical Products in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.09.

This chart shows the closing price for EYES for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Second Sight Medical Products. This rating has held steady since February 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2020HC WainwrightReiterated RatingBuy$2.50High
12/13/2019Dougherty & CoInitiated CoverageBuy$2.00Medium
11/8/2018HC WainwrightSet Price TargetBuy$5.00Medium
8/8/2018HC WainwrightSet Price TargetBuy$5.00High
5/15/2018HC WainwrightSet Price TargetBuy$5.00Low
2/5/2018HC WainwrightSet Price TargetBuy$5.00High
11/6/2017HC WainwrightReiterated RatingBuy$5.00N/A
10/17/2017HC WainwrightSet Price TargetBuy$5.00N/A
8/29/2017HC WainwrightSet Price TargetBuy$5.00Low
8/8/2017HC WainwrightSet Price TargetBuy$5.00Low
7/6/2017HC WainwrightReiterated RatingBuy$5.00Medium
12/25/2016HC WainwrightSet Price TargetBuy$16.00N/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/28/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Second Sight Medical Products logo
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It offers Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device intended to provide artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
Read More

Today's Range

Now: $2.09
Low: $1.97
High: $2.12

50 Day Range

MA: $2.86
Low: $2.09
High: $3.51

52 Week Range

Now: $2.09
Low: $0.95
High: $20.00

Volume

641,005 shs

Average Volume

9,031,072 shs

Market Capitalization

$82.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Second Sight Medical Products?

The following Wall Street research analysts have issued research reports on Second Sight Medical Products in the last twelve months:
View the latest analyst ratings for EYES.

What is the current price target for Second Sight Medical Products?

0 Wall Street analysts have set twelve-month price targets for Second Sight Medical Products in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Second Sight Medical Products in the next year.
View the latest price targets for EYES.

What is the current consensus analyst rating for Second Sight Medical Products?

Second Sight Medical Products currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EYES.

What other companies compete with Second Sight Medical Products?

How do I contact Second Sight Medical Products' investor relations team?

Second Sight Medical Products' physical mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company's listed phone number is (818) 833-5000 and its investor relations email address is [email protected] The official website for Second Sight Medical Products is www.secondsight.com.